Navigation Links
The Foundation for Accelerated Vascular Research Grants $150,000 Wylie Scholar Award for Blood Vessel Research
Date:7/8/2008

Vascular Surgeon-Scientist Ulka Sachdev, M.D., Named 2008 Wylie Scholar

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- The Foundation for Accelerated Vascular Research (FAVR) today announced vascular surgeon-scientist Ulka Sachdev, M.D., of the University of Pittsburgh Medical Center, has been named the 2008 Wylie Scholar in Academic Vascular Surgery. The $150,000 three-year grant was awarded to support her research in understanding the mechanisms that promote blood vessel growth, and to develop new therapies for people suffering from peripheral arterial disease (PAD). PAD is a vascular condition of the lower limbs affecting 12 million Americans that can lead to amputation.

"The goal of the Wylie Scholar program is to provide funding to develop outstanding surgeon-scientists that demonstrate the potential to accelerate the translation of clinical research into patient treatments," said Charles Versaggi, Ph.D., co-chair of FAVR. "Dr. Sachdev's promising research exemplifies the scientific creativity and dedication that Wylie Scholars share."

PAD develops when arteries in the lower limbs become clogged with fatty deposits that limit blood flow. Advanced stages of the disease can lead to critical limb ischemia (CLI), resulting in painful sores, gangrene and limb amputation. Each year CLI results in approximately 150,000 amputations in the United States.

To better understand PAD and ways to treat it, vascular researchers are studying how blood vessels grow. The process known as angiogenesis is complex and poorly understood. Dr. Sachdev is studying a group of molecules called "high-mobility group proteins" (HMGB1) that may act as mediators of angiogenesis.

"My research is directed at developing a better understanding of how HMGB1 may stimulate blood-vessel growth," explained Dr. Sachdev. "This knowledge could allow us to develop revascularization strategies that may reduce the incidents of gangrene, amputations and death." '/>"/>

SOURCE The Foundation for Accelerated Vascular Research
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. The Tug McGraw Foundation Announces 2007 Fundraising Gala
8. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
9. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
10. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
11. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dr. Alan Greene from the kids, health w...eating only organic food. It,s the same benchmark ...nic. , Danville, CA (PRWE...certified organic by the Department of Agriculture... Alan Greene, why not people?, , , , ,In an artic...
(Date:12/4/2008)...a, Dec. 5 Health Care ...ay launched a global partnership to substitute mer...d affordable alternatives. , , The announce...nference on Alternatives to Mercury in Health Care...the Indian NGO Toxics Link. , , "This initi...
(Date:12/4/2008)...omen using Carraguard had no decrease in infection...lthDay News) -- A microbicidal vaginal gel called ...n. , That,s the conclusion of a study that incl... women at three sites in South Africa. , The wo...and told to use one applicator of gel and a condom...
(Date:12/4/2008)..., Dec. 4 MiddleBrook,Ph...nced that it has opened its,administrative and sa...antown,facility will continue to house certain pe...search and development group. The newly leased 14... house up to 60 employees as MiddleBrook,grows. ,...
Breaking Medicine News(10 mins):Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4
...here are certain conditions under which they loose... proteins leading to protein aggregation called as...e for causing neurodegenerative disorders such as ...am from Universitat Autònoma de Barcelona, led by ...
...be effectively fused with other cells to work else...ng to a study.// Researchers at Oregon Health and ...cells may be useful in fighting disease. The rese...Grompe, showed that mice with a disease called tyr...
...Wednesday doctors and hospitals in the global heal...Rs 100 million.// Six hospitals in Chennai, two in... residences of 14 prominent doctors were raided by...Rs.6 million in cash as well as fixed deposits and...
...e responsible for transferring the amino acid Cyst...ucing oxidative stress as Cysteine present in glut...nging activity in brain.// Free radicals are respo...y antioxidants. Professor Raymond Swanson and his ...
Other Medicine News:
(Date:12/3/2008)... potential in newly diagnosed patients with a life...o oral sessions at ASH , , - Exjade results...d patients by significantly reducing toxic iron th...m data from major independent breast cancer trial ...nt strategy, Femara vs. tamoxifen , , - Mul...
(Date:12/3/2008)...irstCall/ -- Wyeth Pharmaceuticals,a division of... submitted a,marketing authorization application ... approval to market its investigational 13-valent ...s and young children. Wyeth is seeking an,indica...D) caused by the 13,serotypes included in the inv...
(Date:12/2/2008)... -- Researchers using functional,MRI (fMRI) have ...rain,responsible for suppressing memory is dysfun... psychiatric disorders. Results of the study will ...adiological Society of North America,(RSNA). , ... stress-related disorders,traumatic memories are...
(Date:12/2/2008)...rizon Therapeutics, Inc., a,privately held biopha...tal,Phase 3 trials evaluating its lead investigat... endpoints. HZT-501, a novel, proprietary fixed-do...amotidine, demonstrated a,statistically significa...ti-inflammatory drug (NSAID)-induced upper gastroi...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference 8642 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 1LCA Vision Reports Third Quarter 2008 Financial Results 27857 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 3LCA Vision Reports Third Quarter 2008 Financial Results 27857 4LCA Vision Reports Third Quarter 2008 Financial Results 27857 5LCA Vision Reports Third Quarter 2008 Financial Results 27857 6LCA Vision Reports Third Quarter 2008 Financial Results 27857 7LCA Vision Reports Third Quarter 2008 Financial Results 27857 8LCA Vision Reports Third Quarter 2008 Financial Results 27857 9LCA Vision Reports Third Quarter 2008 Financial Results 27857 10LCA Vision Reports Third Quarter 2008 Financial Results 27857 11LCA Vision Reports Third Quarter 2008 Financial Results 27857 12LCA Vision Reports Third Quarter 2008 Financial Results 27857 13Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 1Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 2Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 3
...ON, March 06, 2007 /PRNewswire/ -- Up to two milli...p to 600,000,hospitalized. Its primary complicatio...ives annually -- more than breast cancer and,AIDS ...sease may be,at increased risk for DVT, because th...clots and pooling. Respiratory tract infection,may...
...E, Mass., March 06, 2007 /PRNewswire-FirstCall/ --... three completed,Phase III multi- center clinical ...acement therapeutic will be presented during,the N...al Meetings,taking place April 10th through 14th i...a are scheduled to be presented on,Wednesday, Apri...
Other Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4
... at Once , To increase efficiency and throughput ... adapt to the narrow well spacing. Thats exactly w... Available with Impact or Impact2 software (see Im...signed to allow you to transfer an entire column o...
Designed to create a near bloodless field and provide myocardial protection during target vessel anastomosis. Its unique internal coil and tapered tip have been designed to allow easy, atraumatic ins
...y is used for cardiac and great vessel reconstruct...araldehyde-treated bovine pericardium and offers s...suturability and handling over synthetic patches. ... ability to prevent calcification and the complica...
Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide
Medicine Products: